Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients
Rita De Sanctis(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Monica Zuradelli(Humanitas University), Alessandro Viganò(Sapienza University of Rome), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Emanuela Ferraro(University of Milan), Elisa Agostinetto(Université Libre de Bruxelles), Agnese Losurdo(Humanitas University), Lidija Antunovic(Humanitas University), Giovanna Masci(Humanitas University)
Cited by 20
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743